The M134 bomblet was a U.S. chemical sub-munition designed for use in the Honest John rocket during the 1950s. The weapon was never mass-produced and was supplanted in 1964 by an improved design, the M139.
The M134 bomblet, developed as the E130, or E130R1 bomblet, began development in the early 1950s. While the weapon was not yet battle-ready, or ready for mass-production, in 1960, work on the bomblet dated back to at least 1953. By 1964 the bomblet design had been improved and the smaller M139 was adapted for use with the rocket warheads utilized by the M134. Thus, the M134 was never mass-produced; by the time the missile warhead and the M134 were ready for production they had been supplanted.
The M134 bomblet was designed for the M190 Honest John rocket warhead. The bomblets carried sarin nerve agent and when the missile was fired the bomblets were released 5,000 feet above their target. When the time came for the sub-munitions to be released a mechanical time fuze would cut the warhead's skin and the bomblets were released. The weapon could effectively saturate an area 1,000 meters in diameter with chemical agent.
The Honest John held 356 of the 115 mm M134s. The spherical M134 was 4.5 inches around and constructed of ribbed steel; its interior held about 1.1 pounds (0.50 kg) of sarin (GB). The U.S. Army Chemical Corps originally planned to use the M134 as a VX dissemination method as well, but later regarded this use as ineffective and scrapped the plan.
The warhead meant to carry the M134 was classified and went into production on April 14, 1960, the M134, however, was not ready for production at that time. The M134 had a host of issues which impeded its development. Problems with the fuze system, and a tendency toward unacceptable pressure build-up in filled munitions were among the problems encountered during development. The problems with the M134 delayed the rocket-delivered nerve agent program. By 1964 the M139 bomblet was ready for production. The M139 was superior to the M134: its glide angle of 22° allowed it better agent coverage.
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 Kirby, Reid. "The CB Battlefield Legacy: Understanding the Potential Problem of Clustered CB Weapons", Army Chemical Review, pp. 25-29, July–December 2006, accessed January 5, 2009.
- ↑ 2.0 2.1 2.2 2.3 2.4 2.5 2.6 "Summary of Major Events and Problems - United States Army Chemical Corps: Fiscal Year 1960", April 1961 U.S. Army Chemical Corps Historical Office, via Office of Scientific & Technical Information, U.S. Department of Energy, accessed January 5, 2009.
- ↑ 3.0 3.1 Smart, Jeffery K. Medical Aspects of Chemical and Biological Warfare: Chapter 2 - History of Chemical and Biological Warfare: An American Perspective, (PDF: p. 51), Borden Institute, Textbooks of Military Medicine, PDF via Maxwell-Gunter Air Force Base, accessed January 5, 2009.
|This page uses Creative Commons Licensed content from Wikipedia (view authors).|